Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month Why Is Terns Pharmaceuticals (TERN) Stock Gaining Today? - Terns Pharma (NASDAQ:TERN)

Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month Why Is Terns Pharmaceuticals (TERN) Stock Gaining Today? - Terns Pharma (NASDAQ:TERN)

Monday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) revealed topline data from its Phase 1 single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 dosed once-daily (QD) in healthy adults with obesity or overweight. The clinical trial results showed TERN-601 was well tolerated and demonstrated dose-dependent, statistically significant placebo-adjusted mean…

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity - Pipelinereview

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 FOSTER CITY, CA, USA I September 09, 2024 I Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TER…

Terns’ oral GLP-1 passes Phase 1 test with promising weight loss after one month

Terns Pharmaceuticals unveiled early-phase weight loss data from an oral GLP-1 agonist that it says could be more tolerable at higher doses than currently marketed GLP-1 drugs administered the same way. In the multiple ascending dose portion of Terns’ Phase 1 trial, 67% of patients taking the highest 740 mg

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Green Stock News for the New Green Economy.